Real-world study of primary membranous nephropathy
Part of Kidney & urinary clinical trials.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a kidney biopsy that shows primary membranous nephropathy (PMN).
- You must be 18 years or older.
- You must have had at least 3.5 grams of protein in your urine over 24 hours, on average, even after taking blood pressure medicines called ACE inhibitors or ARBs for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
This trial tests if finerenone, a medicine that may protect the kidneys, can help people with primary membranous nephropathy (a kidney disease that causes protein in urine). It is for adults who are already taking a standard blood pressure medicine but still have protein in their urine.
This trial tests an investigational drug called budoprutug for people with primary membranous nephropathy, a kidney condition. The goal is to see if the drug can reduce protein in the urine and help protect kidney function.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This study tests a new drug called JMT601 for people with primary membranous nephropathy, a kidney condition that causes protein in the urine. The goal is to see if JMT601 is safe and effective in reducing protein loss and protecting kidney function.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.